摘要
目的探讨依达拉奉注射液对治疗急性脑梗死的疗效。方法选择72h内发作的急性脑梗死患者102例,随机分为依达拉奉组(51例)和对照组(51例),分别于治疗前和治疗后2周进行临床疗效和日常生活能力评定。结果治疗2周后,依达拉奉组有效率和显效率分别为94.1%和62.7%,对照组有效率和显效率分别为68.6%和38.8%,两组相比差异具有统计学意义(P<0.01);依达拉奉组和对照组的日常生活能力评分(ADL)较治疗前提高,且依达拉奉组与对照组比较,改变更为明显,差异具有统计学意义(P<0.01)。结论依达拉奉对急性脑梗死患者有较好的疗效,值得推广应用。
Objective To explore the effects of edaravone on acute cerebral infarction （ACI）patients. Methods 102 ACI patients who had an onset within 72 hours were allocated to edaravone group （51 cases） and the control group（51 cases）. The clinical effect and activities of daily living（ADL） evaluation were used in the two groups before treatment and after. Results The effective power and excellence rate were 94. 1% and 62.7% with edaravone group after 2 weeks, and the effective power and excellence rate were 68.6% and 38.8% with the control group, There was a significant difference in the two groups （P 〈 0.01 ） , the scores of ADL with the two groups after treatment were higher than before treatment, but edaravone group changes more obvious than the control group （ P 〈 0. 01 ）. Conclusion Edaravone has a higher curative effect with ACI, it is worthy to be recommended for clinical application.
出处
《中国实用医药》
2008年第25期15-16,共2页
China Practical Medicine
关键词
依达拉奉
急性脑梗死
临床疗效
Edaravone
Acute cerebral infarction
Clinical curative effect
